BOLT
Bolt Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.31
+6.68%Price chart
Sep 21Sep 24Sep 29Oct 2Oct 7Oct 12Oct 15Oct 20
Key dataOct 20, 2026
Open$4.29
From 52W high−39.21%
Volume28908.00
Market cap$8.30M
P/E (TTM)—
P/S (TTM)1.8x
Div yield—
Key dataOct 20, 2026
Open
$4.29
From 52W high
−39.21%
Volume
28908.00
Market cap
$8.30M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
P/E (TTM)
—
RSI (14)
61.0
MomentumView details →
1D Return
+6.68%
YTD Return
−21.37%
SummaryUpdated Jun 1, 2026
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) is a clinical-stage biotechnology company founded in 2015 and headquartered in Redwood City, California. The company went public in February 2021 and focuses on developing innovative immuno-oncology therapies designed to harness the body's immune system to eliminate cancer cells. Originally incorporated as Bolt Therapeutics, Inc., the company changed its name to Bolt Biotherapeutics in July 2015 to better reflect its focus on biological therapeutics. The company has undergone significant strategic restructuring in recent years, including substantial workforce reductions and pipeline prioritization to extend its operational runway.
Similar companies
Latest newsMore news →
Bolt Biotherapeutics amended its lease with HCP LS Redwood City LLC, accelerating the lease expiration to December 31, 2027, or earlier upon a Corporate Transaction, and providing for a $4.5 million termination payment upon such a transaction.14d agoBolt Biotherapeutics reported its financial results for the second quarter ended June 30, 2026, and provided a business update.70d ago